Scientists deliberately infect older adults with RSV to unlock immune secrets

NCT ID NCT07713628

Not yet recruiting Knowledge-focused Sponsor: Imperial College London Source: ClinicalTrials.gov ↗

First seen Jul 20, 2026 · Last updated Jul 21, 2026 · Updated 1 time

Summary

This study gives healthy volunteers aged 65 to 75 a carefully measured dose of RSV B virus to see how their immune system responds. Participants stay in a quarantine unit for 10 days for close monitoring and daily samples. The goal is to understand how RSV infection progresses in older adults and to gather data that could improve future vaccines and treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: RSV B challenge virus
What this could lead to: If successful, this study could help develop better vaccines or treatments for RSV in older adults, who are at higher risk for severe illness.
What could go wrong: This is a small, early-stage human challenge study with only 20 participants, so results may not apply to the broader population. There is a risk of mild to moderate RSV symptoms.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RSV are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RSV

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.